The latest report by IMARC Group, titled “Pancreatic Cancer Therapeutics and Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global pancreatic cancer therapeutics and diagnostics market size reached US$ 3.96 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.08 Billion by 2028, exhibiting a growth rate (CAGR) of 7.46% during 2023-2028.

Pancreatic cancer therapeutics and diagnostics encompass a range of medical procedures employed for the diagnosis and treatment of pancreatic cancer. They include ultrasound, computerized tomography (CT) scans, positron emission tomography (PET) scans, and magnetic resonance imaging (MRI). These pancreatic cancer therapeutics and diagnostics methods aid in monitoring the tumor’s location and detecting abnormal cell growth in the pancreas. They facilitate the performance of biopsies, which involve the removal of a small tissue sample for microscopic examination. Pancreatic cancer therapeutics and diagnostics even aid in laboratory investigations, such as complete blood count (CBC), liver enzyme tests to assess biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. Consequently, they find widespread applications in hospitals and specialized centers across the globe.

Request Your Sample Report Now: https://www.imarcgroup.com/pancreatic-cancer-therapeutics-diagnostics-market/requestsample

Pancreatic Cancer Therapeutics and Diagnostics Market Trends and Drivers:

Pancreatic cancer therapeutics and diagnostics market is primarily driven by the expanding elderly population and the elevating emphasis on advancing molecular biology, drugs, and diagnostic technology. Besides this, the growing healthcare industry and the escalating need for chemotherapy to control the growth and division of pancreatic cancer cells are also positively influencing the market growth. Moreover, the inflating investments by government bodies across numerous countries in clinical trials for pancreatic cancer and exploring the use of DNA repair inhibitors in combination with chemotherapy are acting as significant growth-inducing factors. Apart from this, the introduction of humanized monoclonal antibodies by leading market players that stimulate the anti-tumor immune response for targeting esophageal, gastroesophageal junction, and pancreatic cancer and the development of kit-based testing methods to detect pancreatic cancer through evaluation of genomic instability and identification of BRCA1 and BRCA2 variants are expected to bolster the pancreatic cancer therapeutics and diagnostics market in the coming years.

Report Segmentation:

The report has segmented the market into the following categories:

Type Insights:

• Diagnostics
  • Imaging
  • Biopsy
  • Endoscopic Ultrasound
  • Others
• Treatment
  • Targeted Therapies
  • Chemotherapy
  • Surgery
  • Others

Application Insights:

• Hospitals
• Clinics
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Immunovia AB
• Novartis AG
• Pfizer Inc.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

Email: [email protected]

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal